# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

> **NCT05677035** · PHASE1 · COMPLETED · sponsor: **Hyundai Pharm** · enrollment: 20 (actual)

## Conditions studied

- Contraception

## Interventions

- **DRUG:** LINO-1713 1 tablet
- **DRUG:** LINO-1713 once a day for 24 days

## Key facts

- **NCT ID:** NCT05677035
- **Lead sponsor:** Hyundai Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-11
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05677035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05677035, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05677035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*